Who can participate in the BRAVESST$_2$ Clinical study?

You may be eligible if you:

- Are 18 years or older
- Not had surgery within the last 90 days
- Not had prior treatment with monomethyl auristatin E (MMAE) (synthetic derivative of natural substance called dolastatin 10)

The study team will review additional requirements to confirm your eligibility for participation in the study. If you choose to participate, you can choose to leave the study at any time at your own discretion.

What does Participation Involve?

Participation in a study involves a screening phase (up to 28 days), treatment with IV (intravenous, which means into your vein) medication every 21 days until stopped, and follow-up visits 30 days post-treatment, with long-term check-ins every 3 months. Optional tumor biopsies may be requested.



- Participants can choose to participate or leave the study at any time at their own discretion.
- The study drug, study lab tests, imaging, study procedures, and safety assessments are provided at no cost.
- If you travel to the research center for your study visits, travel expenses may be reimbursed.

Let's talk about what's next

You don't have to face this alone.
We are here to help you understand if this study could be right for you.
Contact our study team:

Crinetics_BRAVESST2_17500_ParticipantBrochure_v1.0_08/2025 _NP-9682-0001

EXPLORING NEW OPTIONS: FOR PARTICIPANTS WITH NEUROENDOCRINE NEOPLASMS (NET OR NECS) OR OTHER SOLID TUMORS THAT EXPRESS SST2

Introducing **BRAVESST$_2$**, a clinical study to test a potential new investigational IV (intravenous) medication (CRN09682) in participants with progressive metastatic Somatostatin Receptor Type-2 (SST2) expressing Neuroendocrine Tumors (NETs), Neuroendocrine Carcinomas (NECs) and other SST2-expressing solid tumors

BRAVESST$_2$ STUDY

You have received this brochure because we are offering you an opportunity to participate in a new clinical study called the **BRAVESST$_2$**.

This brochure will give you important information to help you understand all the details of **BRAVESST$_2$** so you can decide if you want to participate in this study.

What is a clinical study?

You might hear the terms “clinical trial” or “clinical study”— they mean the same thing

A **clinical study** is designed to evaluate how safe and effective an investigational drug is in treating a specific disease or condition. The results of clinical studies help regulatory agencies decide if an investigational drug should be made available to patients. These clinical studies help answer important questions like:

- Does the new treatment work?
- What’s the best dosage?
- How does it compare to existing treatments?
- What side effects might it cause?

Safety and Ethics: Before any study begins it is carefully reviewed and approved by an independent ethics committee (in Europe) or Institutional Review Board (IRB) in US. This ensures that the study meets strict safety and ethical standards

Results collected from clinical studies have led to thousands of medications and devices becoming available to patients all over the world.

Understanding the Phases of a clinical study

Clinical studies are conducted in different phases to ensure that new study medications are safe and effective.
Each phase has a specific goal, participant group, and focus. The BRAVESST$_2$ trial is a Phase 1/2 study, which means it combines two early steps: testing for safety and checking if the treatment works.

Phase	Goal	Participants	Focus
1	Test the SAFETY of a new treatment	A SMALL group of people receives increasing doses	Determining the best dosage and identifying any side effects
2	To see if the treatment works	A larger group of people who have the condition the treatment is intended for	Evaluating effectiveness and further assessing safety

Why is the BRAVESST$_2$ study being conducted?

This study is being conducted to test a potential new investigational medication, called CRN09682, for participants with metastatic (cancer spreading and advancing from original location to other parts of the body) or local advanced Neuroendocrine Tumors (NETs), Neuroendocrine Carcinoma (NEC) or other solid tumors that are SST2 (found on the surface of a group of cancerous cells) positive. Some examples of these are:

- Pancreatic, lung, or gastrointestinal Neuroendocrine Tumors (NETs)
- Small or Large Cell Lung Cancer
- Extra-pulmonary neuroendocrine carcinoma
- Colorectal, gastric, breast, hepatocellular, nasopharyngeal carcinomas, or Merkel cell carcinoma and melanoma

This investigational drug will be administered as an **infusion** (**intravenous,** which means into your vein) and has been designed to selectively target SST2 expressing tumor cells and deliver an anti-tumor agent (MMAE) directly to those cells that may help stop or slow down the growth of the tumor. Time will vary and may take between 30 – 90 mins; your study team will keep you informed.

The BRAVESST$_2$ trial is a first-in-human study, meaning this is the first time the study medication, CRN09682, is being tested in people. It has not been approved by any regulatory authority.

What are the risks and benefits of participating in the BRAVESST$_2$ clinical study?

There are various risks and benefits associated in participating in any clinical study. The informed consent document for the study will provide a comprehensive list of both risks and possible benefits. Additionally, the study doctor and clinical site team will answer any questions you may have at any time.

Here are reasons individuals choose to participate in clinical studies, including:

Early access: You will have the opportunity to receive an investigational drug that is not yet available to the public.

Comprehensive care: Throughout the study, you will receive close monitoring and care from our dedicated medical team

Contribution to research: Your participation will help advance medical research and potentially benefit others with similar conditions in the future.